DAX24.915 +0,3%Est505.985 -0,4%MSCI World4.343 -0,1%Top 10 Crypto8,7200 +5,5%Nas22.547 -0,2%Bitcoin58.008 ±0,0%Euro1,1863 -0,1%Öl67,75 +0,3%Gold5.043 +2,5%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Siemens 723610 Rheinmetall 703000 Siemens Energy ENER6Y Deutsche Telekom 555750 SAP 716460 Amazon 906866 NVIDIA 918422 Mercedes-Benz Group (ex Daimler) 710000 Lufthansa 823212 Microsoft 870747 Deutsche Bank 514000 BASF BASF11 DroneShield A2DMAA Allianz 840400 Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach Inflationsdaten: US-Börsen letztlich uneins -- DAX geht etwas fester ins Wochenende -- Amazon im Bärenmarkt -- Delivery Hero, pbb, Siemens, RWE, Rivian, Adyen, Apple, Arista im Fokus
Top News
Delisting: Was passiert, wenn eine Aktie von der Börse genommen wird Delisting: Was passiert, wenn eine Aktie von der Börse genommen wird
KW 7: Die Gewinner und Verlierer der MDAX-Aktien der vergangenen Woche KW 7: Die Gewinner und Verlierer der MDAX-Aktien der vergangenen Woche
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Xencor Aktie

Kaufen
Verkaufen
Xencor Aktien-Sparplan
9,80 EUR -0,05 EUR -0,51 %
BMN
11,57 USD -0,06 USD -0,52 %
nachbörslich
BTT
Xencor jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.699,48 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1W96L

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS98401F1057

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolXNCR

Xencor Aktien News

DatumMeistgelesen
BusinesswireXencor to Participate at Upcoming Investor Conferences
BusinesswireXencor Reports Third Quarter 2024 Financial Results
BusinesswireXencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
Wer­bungXencor-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
BusinesswireXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel Diseases
BusinesswireXencor Announces Upcoming Change to Board of Directors
BusinesswireXencor Announces Closing of Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
BusinesswireXencor Announces Pricing of $175 Million Public Offering of Common Stock
BusinesswireXencor Announces Proposed Public Offering of Common Stock
BusinesswireXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology Programs
BusinesswireXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024
BusinesswireXencor Reports Second Quarter 2024 Financial Results
BusinesswireXencor Regains CD20 x CD3 Bispecific T-Cell Engager
BusinesswireXencor Reports First Quarter 2024 Financial Results
BusinesswireXencor Appoints Bart Cornelissen as Chief Financial Officer
BusinesswireXencor to Present at Upcoming Investor Conferences
BusinesswireXencor Reports Fourth Quarter and Full Year 2023 Financial Results
BusinesswireXencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update
BusinesswireXencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BusinesswireDane Leone Joins Xencor as Senior Vice President, Corporate Strategy
BusinesswireXencor to Present at the Piper Sandler 35th Annual Healthcare Conference
BusinesswireXencor Sells Portion of Royalties and Milestones from Ultomiris® and Monjuvi® to OMERS Life Sciences for $215 Million
BusinesswireXencor Reports Third Quarter 2023 Financial Results
BusinesswireXencor Presents Preclinical Data from Multiple XmAb® Research Programs at the SITC Annual Meeting
BusinesswireXencor to Host Third Quarter 2023 Financial Results Webcast and Conference Call on November 7, 2023
BusinesswireXencor Announces Planned Retirement of Chief Financial Officer John Kuch
BusinesswireXencor to Present Multiple Posters at the SITC Annual Meeting
BusinesswireXencor Appoints Barbara J. Klencke, M.D., to Board of Directors
BusinesswireXencor Reports Second Quarter 2023 Financial Results
BusinesswireXencor to Host Second Quarter 2023 Financial Results Webcast and Conference Call on August 3, 2023
BusinesswireXencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
BusinesswireXencor Reports First Quarter 2023 Financial Results
BusinesswireXencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
BusinesswireXencor Appoints Nancy Valente, M.D., as Chief Development Officer
BusinesswireXencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
BusinesswireXencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
BusinesswireXencor Reports Fourth Quarter and Full Year 2022 Financial Results
BusinesswireXencor to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023

Xencor News

Xencor News: auf dieser Seite finden Sie alle Xencor News und Nachrichten zur Xencor Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Xencor News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Xencor News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.